Rubius Therapeutics Stock Total Asset
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Rubius Therapeutics fundamentals help investors to digest information that contributes to Rubius Therapeutics' financial success or failures. It also enables traders to predict the movement of Rubius Pink Sheet. The fundamental analysis module provides a way to measure Rubius Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rubius Therapeutics pink sheet.
Rubius |
Rubius Therapeutics Company Total Asset Analysis
Rubius Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Rubius Therapeutics Total Asset | 23.07 M |
Most of Rubius Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rubius Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Rubius Therapeutics has a Total Asset of 23.07 M. This is 99.69% lower than that of the Biotechnology sector and 98.83% lower than that of the Health Care industry. The total asset for all United States stocks is 99.92% higher than that of the company.
Rubius Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rubius Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rubius Therapeutics could also be used in its relative valuation, which is a method of valuing Rubius Therapeutics by comparing valuation metrics of similar companies.Rubius Therapeutics is currently under evaluation in total asset category among its peers.
Rubius Fundamentals
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 | |||
| Current Valuation | 22.18 M | |||
| Shares Outstanding | 90.4 M | |||
| Shares Owned By Insiders | 5.55 % | |||
| Shares Owned By Institutions | 72.61 % | |||
| Number Of Shares Shorted | 1.53 M | |||
| Price To Book | 0.42 X | |||
| EBITDA | (169.55 M) | |||
| Net Income | (179.67 M) | |||
| Cash And Equivalents | 140.71 M | |||
| Cash Per Share | 1.56 X | |||
| Total Debt | 76.15 M | |||
| Debt To Equity | 1.17 % | |||
| Current Ratio | 4.63 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (150.14 M) | |||
| Short Ratio | 0.49 X | |||
| Earnings Per Share | (2.27) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 20 | |||
| Beta | 2.45 | |||
| Market Capitalization | 7.5 M | |||
| Total Asset | 23.07 M | |||
| Z Score | -23.1 | |||
| Net Asset | 23.07 M |
About Rubius Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rubius Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rubius Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rubius Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |